US Patent Office Approves Graphene 3D Patent of the Process for Synthesizing Trifluoroketones

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

(TheNewswire)



October 29, 2019 – TheNewswire - Ronkonkoma, NY – Graphene 3D Lab Inc. (TSXV:GGG) (OTC:GPHBF) (“Graphene 3D” or the “Company”) is pleased to announce the US Patent Office has approved the issuance of the “Process for Synthesizing Trifluoroketones” patent (the “Patent”). The Patent secures the Company’s IP rights used in the procedure (the “Technology”) for producing a certain class of trifluoroketones, chemical compounds used in drug manufacturing. This Technology is designed to deliver high quality compounds that are free from toxic byproducts, which can otherwise appear when using alternative methods.

Furthermore, the Technology that is described in the patent was utilized by the Company during collaborations with a major pharmaceutical industrial partner (see press releases March 29, 2018 and February 21, 2019). The Company successfully implemented its now patented technology at a manufacturing facility in Europe and received installment royalty payments totaling US$202,000 for licensing the Technology.

The product that was produced with the Company’s major partner is now undergoing Phase 2a clinical trials which are expected to finish in February 2020. Data collected during Phase 2a will then be used in Phase 2b efficacy tests.

The Company will explore further potential licensing and royalty arrangements, or a complete sale of its IP.

Daniel Stolyarov, CEO of the Company, stated: “Having another technological process with this kind of potential approved by the US Patent Office marks another major milestone for the Company. We have a strong relationship with a trusted Partner and received royalty payments for the licensing of our technology even when the US Patent Office was still reviewing our patent application. With our IP rights secured and further endorsement for the novelty of our new procedure, we are positioned to explore further potential licensing and royalty arrangements, or a complete sale of the IP.”

Stolyarov added, “We are also very pleased and proud that our technology has the potential to be used for the noble purpose of helping people with illness and relief of their suffering.”

About Graphene 3D Lab, Inc.

Graphene 3D Lab, Inc. is capitalizing on groundbreaking properties of graphene and other advanced materials. The company is offering high-tech solutions in several areas including:


Fine Organic Chemicals: ChemApproachTM is a worldwide supplier of a wide variety of building blocks to R&D facilities in pharmaceutical and agriculture industries, academic institutions, biotechnology, and Hi-Tech companies. This division of Graphene 3D Lab offers a plethora of the substituted aromatic and heterocyclic compounds. Most of these molecules can be further synthesized as medicinally relevant drug candidates. The production scale varies from grams to multi-kilograms quantities. The division’s main expertise lies in the introduction of the various substituents to aromatic rings, a large variety of functional group transformations, and a selective incorporation of halogens in organic molecules, particularly, iodine. These classes of organic molecules have a wide range of application in drug-design, biochemistry, polymer chemistry, electronics and energy. ChemApproach.com

R&D Materials: These diverse materials have a wide spectrum of commercial, research, and military applications. The Company's wholly-owned subsidiary, Graphene Laboratories Inc., currently offers over 100 graphene and related products to a client list comprised of more than 14,000 customers worldwide, including nearly every Fortune 500 tech company and major research university. Some notable clients are: NASA, Ford Motor Co., GE, Apple, Xerox, Samsung, Harvard University, IBM, and Stanford University. The Company's suite of products is available online at the company's e-commerce platform Graphene Supermarket (Graphene-Supermarket.com

3D Printing: The 3D printing division of the Company offers a portfolio of 3D printable filaments. These materials can be purchased through multiple distribution networks worldwide or directly from the web-store BlackMagic3D.com .

High Performance Epoxies: Adhesive materials produced by the company are distributed under G6-EpoxyTM trade name and can be purchased at g6-epoxy.com

The Graphene 3D facility is located in Ronkonkoma, NY and is equipped with material processing and analytical equipment. The company has eight US patent applications pending for its technology. For more information on Graphene 3D Lab Inc., visit www.graphene3dlab.com.

ON BEHALF OF THE BOARD:  Daniel Stolyarov, President & Co-CEO

For More Information:

----------------------------------------------------------------------------- |Commercial Inquiries:  |       Investor Inquiries: | |Daniel Stolyarov |Investor Relations | |Co-Chief Executive Officer |Telephone: (631) 405-5114 | |Telephone: (631) 405-5113 |Email:[email protected]| |Email:[email protected] | | -----------------------------------------------------------------------------  

FORWARD LOOKING INFORMATION

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE.  READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE.  WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

  

Copyright (c) 2019 TheNewswire - All rights reserved.